Getinge AB Series B

2.28 £

Fabricant suédois d'équipements médicaux et solutions de soins intensifs, opérant notamment dans les pour salles d'opération et services hospitaliers.

Price history of Getinge AB Series B
Price history of Getinge AB Series B

Performance & Momentum

6 Months 11.88 %
1 Year 0.51 %
3 Years 20.18 %
5 Years 24.87 %

Strategic Analysis

Getinge AB Series B • 2026

Getinge is a Swedish hospital technology player, positioned in critical equipment for operating rooms, intensive care and sterilization. Its model relies on integrated, recurring solutions at the heart of care pathways, which gives it a defensive position within the medical ecosystem despite a more uneven stock market performance in recent years.

Strengths
  • Position in essential medical equipment that is difficult to substitute in the short term
  • Exposure to the structural needs of hospitals in surgery, intensive care and sterilization
  • European industrial profile with a presence in technical segments where quality and reliability are decisive
Weaknesses
  • Still fragile stock performance, with an underlying trend that has been unconvincing over several years
  • Sensitivity to hospital investment cycles and pressure on healthcare budgets
  • Operational complexity of a multi-segment group exposed to high regulatory and industrial requirements
Momentum

Momentum appears moderately positive, with a short-term rebound that contrasts with an underlying trend that remains weakened over the longer term. For investors, this suggests a stock in a stabilization phase rather than a genuine turnaround, worth monitoring for a more durable improvement in execution and market sentiment.

Similar stocks to Getinge AB Series B

Was this page helpful?

Your feedback helps us improve our research.

Take control
of your investments

Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.

  • Real-time multi-portfolio tracking
  • AI analysis of your positions
  • Counter your cognitive biases
Anantys Invest on iPhone